About Peter Davies

This author has not yet filled in any details.
So far Peter Davies has created 17 blog entries.

binx health partners with global healthcare leader, McKesson, for National Launch of the FDA-cleared binx io platform

binx molecular point-of-care platform poised to transform care for chlamydia and gonorrhea, the two most tested for sexually-transmitted infections

Boston, MA, February 16, 2021

A first-of-kind FDA-cleared infectious disease platform, the binx io provides results in about thirty minutes, which enables diagnosis and treatment of chlamydia (CT) and gonorrhea (NG) to take place in a single visit. The binx io’s test performance has been demonstrated to be on par with central-laboratory testing.

Today, about thirty-five million CT/NG tests are processed at central laboratories, with virtually all patients leaving a clinic before results are ready. Under this traditional care model, up to 40%[1] of patients who are subsequently determined to be positive do not return for treatment once they leave the clinic, leading to further infection spread and comorbidities.

The binx io is poised to change all of that, by delivering results within the time window of a typical OB-GYN visit. Initial distribution of the binx io will be into settings that are certified to perform moderate or high complexity diagnostic tests under the Clinical Laboratory Improvement Amendments (CLIA). The binx io platform also may be used in satellite point-of-care (POC) settings designated under such moderate or high complexity certificates. binx has also completed its CLIA waiver study and submitted a request to the Food and Drug Administration (FDA) in 2020 to classify the platform as CLIA waived, which, upon FDA clearance, will enable distribution to the 200,000+ CLIA-waived locations nationwide.

“At binx we consider evidence-based care and consumer convenience central to all we do,” said Jeffrey Luber, binx health’s Chief Executive Officer. “Today’s announcement is a win-win-win for clinics, patients and the public health and we are especially proud of this new distribution partnership for national reach.”

binx health has partnered with global healthcare leader McKesson for the sale and distribution of the binx io platform.

For more information about binx io, visit mybinxhealth.com/point-of-care or contact info@mybinxhealth.com.

2021-03-03T17:21:54+00:00March 3rd, 2021|

Symetrica appoints John Zangardi, a former advisor to the US Secretary of Defense for Information Management / Information Technology to its Board of Directors

Symetrica Inc, an innovative, leading radiation detection and identification business in Massachusetts has announced a material business impact from the appointment of John Zangardi, a former advisor to the US Secretary of Defense for Information Management / Information Technology as a Non-Executive Director to the Symetrica Board. Symetrica Inc. operates internationally and has successfully provided the Homeland Security and Military radiation detection market sectors with a wide range of innovative solutions for over 10 years.


2021-03-03T17:33:00+00:00March 1st, 2021|

Micrima appoints Adrain Waller as CEO

Micrima is pleased to announce after a professional search to find a new CEO with the right blend of MedTech and commercial experience, we have appointed Adrian Waller who will start on the 1st Jan 2021. Adrian has extensive Medical device experience together with a technical background (aerospace engineering) and for the last six years has been General Manager of Fujifilm Medical`s diagnostic medical-imaging business in the UK. During that time he was responsible for all UK activities, including commercial which grew significantly, in all areas, under his leadership. Prior to Fujifilm, Adrian spent three years with GE Healthcare where he was brought in to assist and restructure the team as they exited the National Programme for IT (NPfIT) before helping them commercialise a range of very specialised IT Solutions for the MedTech sector.

Adrian said in a brief statement to investors “I’m incredibly excited about joining Micrima at such a key stage of its development.  The potential of the MARIA® system to transform the diagnosis of breast cancer is clear and the opportunity to work with the team to accelerate the products adoption and continued development was something that I had to get involved with.  I’m really looking forward to joining the team in the new year and using my market knowledge, network, and business management skills to help Micrima make a difference to the ~600k ladies that die of breast cancer, every year” We look forward to a more in-depth article with Adrian when he formally joins the company in 2021

2021-03-03T17:21:02+00:00February 1st, 2021|

New York Film Academy Selects binx health for COVID-19 Testing, Creating Instant Platform for Broad Health Offerings Across Multiple Campuses

binx health is excited to announce it will provide university-wide COVID-19 testing for the New York Film Academy (NYFA), among the most highly regarded visual and performing arts colleges in the world. The binx platform will enable at-home, in-dorm and on campus specimen collection, providing healthcare convenience for NYFA students, faculty and staff at campuses in New York, Los Angeles and Miami.

With US colleges representing 19 of the top 25 vectors of transmission of COVID-19, the binx solution is being deployed across campuses to keep students and faculty safe. As California, Florida and New York currently comprise three of the four states with the highest daily case rates in the country, and are locations that include NYFA campuses, there continues to be a strong need for the convenient, high quality testing, which binx is offering to NYFA and to institutional partners globally.

“At NYFA, our priority is to create a safe and healthy learning and working environment for our students, faculty and staff. With a geographically diverse student and employee base, it was of the utmost importance that our community has access to high quality, accurate, and accessible testing and easy-to-use sample collection, a solution NYFA will be employing on campus and that can also be offered conveniently at-home and in-dorm,” said NYFA President, Michael Young. “With the binx COVID-19 testing solution now in place, our community has the opportunity to easily expand and evaluate other health testing using at-home collection kits with the support and solutions of binx health.”

“We applaud NYFA for their commitment to care, and to their communities, and we look forward to partnering with them across their wellness initiatives,” said Jeffrey Luber, binx Chief Executive Officer.

2021-03-03T15:02:03+00:00January 26th, 2021|

VQ Communications, the Chippenham, UK based supplier of Video Conferencing Management Software is now a CISCO Solutions Plus Partner

VQ is now a Cisco Solutions Plus Partner

This is a big day for VQ and I’m really pleased and excited to announce that VQ Conference Manager can now be purchased through Cisco. Thank you to everybody at Cisco who made it possible and championed VQ. Thank you to our partners and customers for their risk taking and votes of confidence over the years leading up to this result.

This isn’t all about VQ; the real message is CMS plus VQ and enabling enterprise wide audio and video conferencing. For example, over the last couple of days I’ve seen data from 4 large CMS/VQ systems with in-call participant counts of 8000+, 7000+, 3000+ and 1000+ for large periods of the day; that’s over 20,000 people in call on just 4 of the 150+ VQ systems in the field. The numbers clearly show how CMS based systems deliver services on a completely different scale from previous bridge generations. The CMS platform is underpinning organizations, delivering the promise of the digital workplace and enabling a degree of business as usual in these difficult times.

Secure, VQ Conference Manager is mostly installed as an on-premises solution although we also have a number of service provider customers and are starting to see secure cloud offerings being evaluated. Customers are located globally and include a wide range of categories including enterprise, health, government and defence.

Our roadmap looks great and should start to see the next round of changes from mid-May targeted at enabling customers transitioning to CMS as their Codians go end-of-life.

We look forward to working with you.

Take care,


2021-03-03T17:52:18+00:00April 8th, 2020|

Binx Health Receives FDA 510(k) Clearance for Rapid Point of Care Platform

August 12, 2019 (BOSTON) PR NEWSWIRE – binx health, the pioneer in anywhere, anytime testing for women’s health, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its first-of-kind, highly sensitive and specific, molecular point-of-care (POC) diagnostic testing platform, the binx io®.  The binx io platform is a rapid, qualitative, fully-automated test, designed to be easy to use, and intended for use in POC or clinical laboratory settings, providing the world’s first sample-to-answer result in about 30 minutes for the detection of chlamydia (CT) and gonorrhea (NG)—the two most tested-for STIs globally. In the Company’s recently completed 1,523-person, multi-center clinical study, 96% of patient samples were processed on the binx io by non-laboratorians in a POC setting.


2021-03-03T15:02:26+00:00September 19th, 2019|

Micrima raises additional £4.4 million for Breast Cancer screening technology

Micrima, the Bristol-based breast imaging company, has raised £4.4 million in additional equity funding led by Technology Venture Founders, The Angel CoFund (ACF), and Venture Founders plus a group of returning and new individual investors. This brings the total amount raised by Micrima to £10.7m.

Roy Johnson, Micrima’s Executive Chairman, said, “I am very happy to announce the completion of our latest funding round, which provides us with the capital we need to move our initial MARIA product into full commercial launch and follow this swiftly with the enhanced functionality that the system is capable of achieving. The market has been prepared over the past 18 months through the publication of our historical clinical trial data, and attendance at numerous congresses and trade shows to showcase our breakthrough technology. As a result, we have many influential clinicians and partners anticipating the launch of MARIA later this year. We look forward to putting the product we have worked so hard to create into their hands for the first time.”


2019-04-10T17:40:27+00:00June 21st, 2018|

Dynmark acquired by AIM listed dotdigital Group plc

dotdigital Group Plc (AIM:DOTD), the leading provider of intuitive software as a service (“SaaS”) and managed services to digital marketing professionals, through the ‘dotmailer’ platform, announces that it has completed the acquisition of the COMAPI group of companies. COMAPI (the trading name for Dynmark), a fast-growing business focused on the omni-channel messaging and cloud communication market, has been acquired for a cash consideration of £11 million.


Headquartered in Cheltenham with approximately 30 employees, COMAPI has built a scalable software platform that allows businesses to communicate with their consumers across multiple conversational messaging channels including the growing market for live chat. Comapi’s heavy investment in technology allows it to compete in the CPaaS (communication platform as a service) and ARN markets (alerts, reminders and notification), providing a flexible API (application programming interface) based omni-channel messaging platform and toolkit that facilitates easy integration and rapid deployment to businesses requiring a personalised and two-way customer engagement solution.


COMAPI is a successful brand with strong growth and revenues within the CPaaS market and, with dotdigital’s full support, will continue to work directly with its customers, which include Gap, eBay, TSB, British Airways, Carphone Warehouse and Collect Plus. dotmailer and COMAPI already have numerous shared clients which include Superdry, Hayes Recruitment, Daisy Group and betting giant Ladbrokes.


2019-04-10T17:40:27+00:00December 21st, 2017|

Symetrica wins the Venture category at the BVCA South West Management Team Awards 2017

Symetrica have been announced as the winner of the Venture Category at the British Private Equity & Venture Capital Association’s (BVCA) South West Management Team Awards 2017. Now in their ninth year, the BVCA Management Team Awards recognise and reward brilliant businesses up and down the country that are backed by UK private equity and venture capital investors.

The BVCA’s judges’ commented: “Symetrica has been a pioneer in its radiation detection technology and now has a leading position in homeland security. The judges were impressed with the way Heddwyn Davies had grasped this opportunity in 2016, driving a fourfold increase in sales, notably breaking into the US market, while at the same time bringing out a handheld version of the technology.”

Symetrica will now go forward into the national final to compete against the other UK regions before the national winners are announced at the BVCA Gala Dinner on 30 November in London.


BVCA Management Team Awards

2019-04-10T17:40:27+00:00May 5th, 2017|

Atlas Genetics raises $35m in Series D fundraising

Financing global launch and menu development of Atlas Genetics’ io® molecular testing system

Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces completion of its Series D financing, raising $35 million from a syndicate including all Series C Investors and one new investor, Wondfo Biotech.

Development of the Atlas Genetics io® system has been completed with the successful CE marking of the Chlamydia trachomatis (CT) test announced in February 2016.  This new Series D equity issue will finance the clinical trials and commercial launch of a second test, for detection of both Chlamydia and Gonorrhoea, planned for regulatory approvals in the US around the end of 2017, as well as further development of additional diagnostics menu.  The financing also provides funding to expand cartridge manufacturing capacity at Bespak, Atlas Genetics’ cartridge manufacturing partner.


2019-04-10T17:40:27+00:00February 1st, 2017|

Micrima raises £2.6 million for ground-breaking radiowave breast imaging technology

Micrima, the Bristol-based breast imaging company and developer of a ground-breaking and CE Mark approved radiowave breast imaging system, has successfully closed on a new financing round of £2.6m. The new funding will support accelerated development of its patented MARIA technology, which aims to enable breast screening to become safer, more comfortable and more accessible to a larger proportion of the global female population. The company intends to start the commercialisation of its first system towards the end of this year.

“Breast cancer is the most common cause of death in women between the ages of 35 and 55 in Europe and the leading cause of death for women in many countries. The problem is that many tumours are not discovered early enough, largely due to the difficulty in discriminating between cancers and dense tissue using current imaging technology,” said Roy Johnson, Micrima’s Executive Chairman. “Using harmless radiowaves, the MARIA imaging system is capable of detecting tumours in dense tissue and allows routine and repeated scanning without any of the safety or comfort concerns associated with x-ray mammography. The process takes less than five minutes and avoids painful breast compression.”


2019-04-10T17:40:28+00:00September 5th, 2016|

Covalent Software Limited acquired by Ideagen Plc

TVP portfolio company, Covalent Software, has been acquired by Ideagen Plc, the UK AIM listed provider of information management software to regulated industries.

For Covalent the deal provides significant future growth opportunities in its core financial and public services markets as well as opportunities for the enlarged group to expand its governance, risk and compliance (GRC) presence in healthcare, local government, finance and banking.

The deal marks a successful exit for Covalent’s previous funders. TVP’s Nick Simmonds said: “It has been a pleasure working with Peter McHugh and the team at Covalent Software and we are delighted with the way in which Covalent has developed into a technology leader in the GRC space.  We wish the company every success for the future.”


2019-04-10T17:40:28+00:00August 8th, 2016|

Atlas Genetics Gains EU CE Approval for First Product

Approval of Chlamydia test for marketing and sale in Europe

Atlas Genetics Ltd, the Bath, UK based, ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has received approval to CE Mark its Chlamydia trachomatis (CT) test to be launched on the Company’s io® platform.  By meeting the requirements of the IVD Directive (98/79/EC), the CT test is now cleared for sale within the European Union.

The launch of the io® CT test signals a new era in ultra-rapid molecular diagnostics.  This is the first molecular POC test for a Sexually Transmitted Infection (STI) to enter the market, capable of delivering test results in just 30 minutes.  With the speed and accuracy of the io® CT product, the testing and treatment of patients within a single, brief visit to the clinic now becomes a reality.


2016-02-09T10:06:50+00:00February 9th, 2016|

Sky partners with Object Matrix

Object Matrix, the trusted storage partner to the media and entertainment industries, today announces that Sky, Europe’s leading entertainment company with over 21 million customers, has integrated MatrixStore object storage into Avid Interplay production workflows at its headquarters in London.

Sky is Europe’s leading investor in television content, with a combined programming budget of £4.9bn, commissioning its own original programming and entering into strategic partnerships to deliver the best possible TV viewing experience for customers. With production infrastructure often used to capacity, the Sky production team looked to find a solution that could not only scale into future workflows but also take the strain off the editing storage with seamless integration into current workflows.


2016-05-30T15:33:34+00:00February 2nd, 2016|

Symetrica’s Radiation Detection and Identification Technology to be deployed by US Department of Homeland Security

Symetrica has announced that its patented radiation detection and identification technology will be deployed in the latest Handheld Radioisotope Identification Devices (RIIDs) that Smiths Detection Inc. has agreed to supply to the U.S. as part of a contract with the Department of Homeland Security (DHS). Symetrica’s Discovery Technology is at the heart of the Smiths Detection RadSeeker handheld radiation detectors for which the DHS Domestic Nuclear Detection Office (DNDO) recently awarded an IDIQ (indefinite delivery/indefinite quantity) contract with a maximum value of $143 million for the technology, its maintenance and associated training.


2019-04-10T17:40:28+00:00January 28th, 2016|

Technology Venture Partners appoints Richard Green as Non-executive Chairman

Technology Venture Partners the technology venture capital firm has announced the appointment of Richard Green as Non-executive Chairman.

Richard Green joined Kleinwort Benson Development Capital in 1988 and was a founder in 2001 of the spin-out business which became August Equity LLP, where he was the Managing Partner until 2009 and then Chairman until his retirement in April 2014.  He is a past chairman of the British Venture Capital Association and is currently a non-executive director of AIM-quoted Qannas Investments Limited, a non-executive director of Northern Venture Trust PLC, a member of the Advisory Board of Finance for Business North East and a member of the Advisory Committee of the European Investment Bank’s Growth Finance Initiative.


2019-04-10T17:40:28+00:00July 16th, 2015|

Bristol venture team set up Technology Venture Partners in spin-out from YFM Equity Partners

The Bristol team of YFM Equity Partners have taken over managing the South West Ventures Fund through a newly formed independent venture capital fund manager, Technology Venture Partners.

The South West Ventures Fund was established as one of the UK’s nine Regional Venture Capital Funds to invest up to £2m of risk capital into high growth small businesses. The fund is now fully invested and the portfolio includes Dynmark, a cloud based mobile intelligence and messaging platform and Micrima, which has developed innovative technology for breast cancer screening based on radiowaves instead of X-rays.

The spin-out will see the South West Ventures Fund continue to be managed by the three founding partners of Technology Venture Partners, Peter Davies, Nick Simmonds and Julian Dennard. Technology Venture Partners will focus on investing in emerging UK technology companies.


2019-04-10T17:40:28+00:00May 23rd, 2014|
Go to Top